A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas

Table 1

Dose escalation scheme for the combination treatment with belinostat and doxorubicin.

Phase	Purpose	Eligibility	Cohort	Bel (mg/m^2)	Dox (mg/m^2)
I	Dose escalation	pts with STS and other solid tumours	1	600	50	3
			2	600	75	7
			3	800	75	9
			4	1000	75	6
II	MTD expansion	pts with STS only	Expansion 1	MTD	MTD	20 (16 plus 4 from cohort 4)
			Expansion 2	MTD	MTD	0

STS: soft tissue sarcoma.
MTD: maximum tolerated dose.